<div class="white-sheet">
    <div class="content-slide">

<!-- Secondary scene 1 -->
    <div class="content secondary-scene">
        <!--<h1>Content</h1>-->
        

                <div class="title-bar red"></div>

                <div class="wrapper slide-2-6-2-1">

                    <div class="vertical-nav">
                        <ul class="seven">
                            <li class="active"></li>
                            <li></li>
                            <li></li>
                            <li></li>
                            <li></li>
                            <li></li>
                            <li></li>
                        </ul>
                    </div>

                    <div class="popups" style="position:absolute">
                        <div data-effect="fade" data-duration="1000" data-target="references1-overlay" data-width="600" data-height="490" class="references-button show-overlay"></div>
                        <div data-effect="fade" data-duration="1000" data-target="information1-overlay" data-width="600" data-height="490" class="information-button show-overlay"></div> 
                    </div>

                    <div class="slide-title red two-line">
                        Definitive care in severe aplastic anaemia:<br />haematopoietic stem cell transplant
                    </div>


                    <div class="content-container">
                
                       <div class="content-left">
                            <ul>
                                <li><span>HSCT is potentially curative and restores haematopoiesis in patients with severe aplastic anaemia<sup>1,2</sup></span></li>
                                <li><span>It is the treatment of choice for patients with severe aplastic anaemia who have an HLA-matched sibling donor<sup>1,2</sup></span>
                                    <ul>
                                        <li><span>HSCT is also associated with a reduced risk of relapse and evolution of late clonal disorders (e.g. MDS and PNH)<sup>2,3</sup></span></li>
                                    </ul>
                                </li>
                                <li><span>The main source of stem cells include mobilised peripheral blood and bone marrow<sup>1</sup></span>
                                    <ul>
                                        <li><span>Cord blood has been successfully explored as a source of stem cells, but is not the first choice<sup>4</sup></span></li>
                                    </ul>
                                </li>
                                <li><span>Survival 5 years after HSCT may be:<sup>1</sup></span>
                                    <ul>
                                        <li><span>Over 70% for patients aged ≤40 years</span></li>
                                        <li><span>~50–60% for patients aged >40 years</span></li>
                                    </ul>
                                </li>
                            </ul>
                        </div>


                        <div class="content-right">
                            <div class="red-label">
                                Survival after HSC transplant from<br />
                                HLA-matched sibling donors versus alternative<br />
                                (non-identical) donors<sup>5</sup>

                            </div>
                            
                                <img src="media/images/slide_2-6-2-1/picture1.png" alt="" width="442">

                                <p class="small-print">
                                    Acquired severe aplastic anaemia transplantations 1999–2009: the effect of donor type and matched sibling donors versus unrelated donors.
                                </p>
                            
                        </div>

                    </div>

                </div>

                <div class="information1-overlay overlay">

                    <header>Definitive care in severe aplastic anaemia: haematopoietic stem cell transplant</header>

                    <ul>
                        <li><span>HSCT is the only potential cure for aplastic anaemia to date<sup>6</sup></span></li>
                        <li><span>Fewer than 30% of patients will have an HLA-matched sibling donor<sup>7</sup></span></li>
                        <li><span>Survival after transplantation has increased steadily since the 1970s, but complications such as chronic graft-versus-host disease (GVHD; also known as transplant rejection) occur in up to one-third of patients<sup>7</sup></span>
                            <ul>
                                <li><span>Risk of GVHD increases with age, which accounts for decreased survival and long-term morbidity in older patients<sup>1,7</sup></span></li>
                            </ul>
                        </li>
                        <li><span>HSCT from a matched sibling donor is the current standard of care in severe aplastic anaemia<sup>1</sup></span>
                            <ul>
                                <li><span>Although alternative donor transplantation may be pursued, survival is variable and not as high as that observed with donation from a matched sibling (43–94% vs survival consistently over 70% in patients up to the age of 40)</span></li>
                            </ul>
                        </li>
                    </ul>


                </div>


                <div class="references1-overlay overlay">

                    <header>References</header>
                        
                    <ol>
                        <li class="navigateHref" data-navtarget="media/documents/module2/ScheinbergP-2012-Blood-v120p1185.pdf"><span>Scheinberg P & Young NS. <i>Blood</i> 2012;120:1185</span></li>
                        <li class="navigateHref" data-navtarget="media/documents/module2/DeZernA-2011-ExpertRevHematol-v4p221.pdf"><span>DeZern AE & Brodsky RA. <i>Exp Rev Hematol</i> 2011;4:221</span></li>
                        <li class="navigateHref" data-navtarget="media/documents/module2/SocieG-2013-ASHEducation-v2013p82.pdf"><span>Socie G <i>et al. N Engl J Med</i> 1993;329:1152</span></li>
                        <li class="navigateHref" data-navtarget="media/documents/module2/BacigalupoA-2009-HematolOncolClinNAm-v23p159.pdf"><span>Bacigalupo A & Passweg J <i>et al. Haematol Oncol Clin N Am</i> 2009;23:159</span></li>
                        <li class="navigateHref" data-navtarget="media/documents/module2/SocieG-2013-ASHEducation-v2013p82.pdf"><span>Figure adapted from Socie G. <i>Hematology Am Soc Hematol Educ Program</i> 2013;82</span></li>
                        <li class="navigateHref" data-navtarget="media/documents/module2/GuinanEC-2011-HematolAmSocHematolEducProgram-v2011p76.pdf"><span>Guinan EC. <i>Hematology Am Soc Hematol Educ Program</i> 2011;2011:76</span></li>
                        <li class="navigateHref" data-navtarget="media/documents/module2/BrodskyRA-2005-Lancet-v365p1647.pdf"><span>Brodsky RA & Jones RJ. <i>Lancet</i> 2005;365:1647</span></li>
                    </ol>

                </div>


          
    </div>
    <!-- End of secondary scene 1 -->
    <!-- Secondary scene 2 (Static Content) -->
    <div class="content secondary-scene">
         

                <div class="title-bar blue"></div>

                <div class="wrapper slide-2-6-1a">

                    <div class="vertical-nav">
                        <ul class="seven">
                            <li></li>
                            <li class="active"></li>
                            <li></li>
                            <li></li>
                            <li></li>
                            <li></li>
                            <li></li>
                        </ul>
                    </div>

                    <div class="popups" style="position:absolute">
                        <div data-effect="fade" data-duration="1000" data-target="references2-overlay" data-width="600" data-height="490" class="references-button show-overlay"></div>        
                    </div>

                    <div class="slide-title blue">
                        Haematopoietic stem cell transplant
                    </div>


                    <div class="content-container">
                     
                        <ul>
                            <li><span>HSCT is the treatment of choice for children and young adults (aged up to 40 years) with severe aplastic anaemia who have an HLA-matched sibling donor<sup>1</sup></span></li>
                            <li><span>Most candidates are not suitable for optimal HSCT for reasons such as:</span>
                                <ul>
                                    <li><span>Lack of a matched sibling donor<sup>1</sup></span>
                                        <ul>
                                            <li><span>Fewer than 30% of patients will have an HLA-matched sibling donor<sup>2</sup></span></li>
                                        </ul>
                                    </li>
                                    <li><span>Lead time to identify a suitable unrelated donor (UD) <sup>1</sup></span></li>
                                    <li><span>Age<sup>1</sup></span></li>
                                    <li><span>Comorbidities<sup>1</sup></span>
                                        <ul>
                                            <li><span>Contraindications include poor cardiac and or renal function, and the presence of HIV or active hepatitis B or C viral infection<sup>3</sup></span></li>
                                        </ul>
                                    </li>
                                    <li><span>Lack of access to transplantation facilities<sup>1</sup></span></li>
                                </ul>
                            </li>
                        </ul>

                    </div>

                </div>


                <div class="references2-overlay overlay">

                    <header>References</header>
                        
                    <ol>
                        <li class="navigateHref" data-navtarget="media/documents/module2/ScheinbergP-2012-Blood-v120p1185.pdf"><span>Scheinberg P & Young NS. <i>Blood</i> 2012;120:1185</span></li>
                        <li class="navigateHref" data-navtarget="media/documents/module2/BrodskyRA-2005-Lancet-v365p1647.pdf"><span>Brodsky RA & Jones RJ. <i>Lancet</i> 2005;365:1647</span></li>
                        <li class="navigateHref" data-navtarget="media/documents/module2/MedicalNecessityGuidelines-2013.pdf"><span>Medical necessity guidelines. Stem-cell transplantation for aplastic anaemia and Fanconi anaemia. 2013. http://www.cigna.com/sites/careallies/pdf/CA0293_sct_aplastic_anemia.pdf. (accessed November 2013)</span></li>
                    </ol>

                </div>

          
    </div>
    <!-- End of secondary scene 2 -->
    <!-- Secondary scene 3 -->
    <div class="content secondary-scene">
        <!--<h1>Content</h1>-->
        

                <div class="title-bar blue"></div>

                <div class="wrapper slide-2-6-2-1">

                    <div class="vertical-nav">
                        <ul class="seven">
                            <li></li>
                            <li></li>
                            <li class="active"></li>
                            <li></li>
                            <li></li>
                            <li></li>
                            <li></li>
                        </ul>
                    </div>

                    <div class="popups" style="position:absolute">
                        <div data-effect="fade" data-duration="1000" data-target="references3-overlay" data-width="600" data-height="490" class="references-button show-overlay"></div>
                        <div data-effect="fade" data-duration="1000" data-target="information3-overlay" data-width="600" data-height="490" class="information-button show-overlay"></div> 
                    </div>

                    <div class="slide-title blue two-line">
                        Allogeneic sibling haematopoietic stem cell <br />transplant studies
                    </div>


                    <div class="content-container" style="overflow-y:scroll;-webkit-overflow-scrolling: touch">

                        <ul>
                            <li><span>Allogeneic transplant from an HLA-matched sibling donor is curative in the majority of cases and survival rates have improved with time</span></li>
                        </ul>
                            
                
                       <table class="blue">

                            <tr class="odd">
                                <th>Institution/Study</th>
                                <th>Duration of study, years</th>
                                <th>Patients, n</th>
                                <th>Age,(median in years)</th>
                                <th>Graft rejection/failure, %</th>
                                <th>Acute GVHD,* %</th>
                                <th>Chronic GVHD, %</th>
                                <th>Actuarial survival, %</th>
                            </tr>


                            <tr>
                                <td>IBMTR</td>
                                <td>1988–1992</td>
                                <td>471</td>
                                <td>20 (1–51)</td>
                                <td>16</td>
                                <td>19</td>
                                <td>32</td>
                                <td>66 (at 5 years)</td>
                            </tr>


                            <tr class="odd">
                                <td>Vienna</td>
                                <td>1982–1996</td>
                                <td>20</td>
                                <td>25 (17–37)</td>
                                <td>0</td>
                                <td>26</td>
                                <td>53</td>
                                <td>95 (at 15 years)</td>
                            </tr>


                            <tr>
                                <td>EBMT</td>
                                <td>1991–1998</td>
                                <td>71</td>
                                <td>19 (4–46)</td>
                                <td>3</td>
                                <td>30</td>
                                <td>35</td>
                                <td>86 (at 5 years)</td>
                            </tr>


                            <tr class="odd">
                                <td>Seoul</td>
                                <td>1990–1999</td>
                                <td>22</td>
                                <td>22 (14–43)</td>
                                <td>5</td>
                                <td>10</td>
                                <td>33</td>
                                <td>95 (at 5 years)</td>
                            </tr>


                            <tr>
                                <td>Seoul</td>
                                <td>1990–2001</td>
                                <td>64</td>
                                <td>28 (14–43)</td>
                                <td>18</td>
                                <td>31</td>
                                <td>19</td>
                                <td>79 (at 6 years)</td>
                            </tr>


                            <tr class="odd">
                                <td>Hamburg</td>
                                <td>1990–2001</td>
                                <td>21</td>
                                <td>25 (7–43)</td>
                                <td>5</td>
                                <td>5</td>
                                <td>5</td>
                                <td>86 (at 5 years)</td>
                            </tr>


                            <tr>
                                <td>Paris</td>
                                <td>1994–2001</td>
                                <td>33</td>
                                <td>20 (8–42)</td>
                                <td>6</td>
                                <td>0</td>
                                <td>42</td>
                                <td>94 (at 5 years)</td>
                            </tr>


                            <tr class="odd">
                                <td>Taipei</td>
                                <td>1985–2001</td>
                                <td>79</td>
                                <td>22 (4–43)</td>
                                <td>8</td>
                                <td>7</td>
                                <td>35</td>
                                <td>74 (at 5 years)</td>
                            </tr>


                            <tr>
                                <td>Tunis</td>
                                <td>1998–2001</td>
                                <td>31</td>
                                <td>19 (4–39)</td>
                                <td>16</td>
                                <td>11</td>
                                <td>3</td>
                                <td>86 (at 2 years)</td>
                            </tr>


                            <tr class="odd">
                                <td>Seoul</td>
                                <td>1995–2001</td>
                                <td>113</td>
                                <td>28 (16–50)</td>
                                <td>15</td>
                                <td>11</td>
                                <td>12</td>
                                <td>89 (at 6 years)</td>
                            </tr>


                            <tr>
                                <td>London</td>
                                <td>1989–2003</td>
                                <td>33</td>
                                <td>17 (4–46)</td>
                                <td>24</td>
                                <td>14</td>
                                <td>4</td>
                                <td>81 (at 5 years)</td>
                            </tr>


                            <tr class="odd">
                                <td>Seattle</td>
                                <td>1988–2004</td>
                                <td>94</td>
                                <td>26 (2–59)</td>
                                <td>4</td>
                                <td>24</td>
                                <td>26</td>
                                <td>88 (at 6 years)</td>
                            </tr>


                            <tr>
                                <td>Mexico City</td>
                                <td>2000–2005</td>
                                <td>23</td>
                                <td>25 (4–65)</td>
                                <td>26</td>
                                <td>17</td>
                                <td>26</td>
                                <td>88 (at 4 years)</td>
                            </tr>
                            
                        </table>

                        <p class="small-print">*Results are generally for grades II–IV and patients at risk. GVHD, graft-versus-host disease </p>

                    </div>

                </div>

                <div class="information3-overlay overlay">

                    <header>Allogeneic sibling haematopoietic stem cell transplant studies</header>

                    <ul>
                        <li><span>Allogeneic transplant from an HLA-matched sibling donor can cure the majority of patients</span></li>
                    </ul>


                </div>


                <div class="references3-overlay overlay">

                    <header>References</header>
                        
                    <ul>
                        <li class="navigateHref" data-navtarget="media/documents/module2/YoungNS-2006-Blood-v108p2509.pdf"><span>Young NS <i>et al. Blood</i> 2006;108:2509</span></li>
                    </ul>

                </div>


          
    </div>
    <!-- End of secondary scene 3 -->
    <!-- Secondary scene 4 -->
    <div class="content secondary-scene">
        <!--<h1>Content</h1>-->
        

                <div class="title-bar blue"></div>

                <div class="wrapper slide-2-6-2-1">

                    <div class="vertical-nav">
                        <ul class="seven">
                            <li></li>
                            <li></li>
                            <li></li>
                            <li class="active"></li>
                            <li></li>
                            <li></li>
                            <li></li>
                        </ul>
                    </div>

                    <div class="popups" style="position:absolute">
                        <div data-effect="fade" data-duration="1000" data-target="references4-overlay" data-width="600" data-height="490" class="references-button show-overlay"></div>
                        <div data-effect="fade" data-duration="1000" data-target="information4-overlay" data-width="600" data-height="490" class="information-button show-overlay"></div> 
                    </div>

                    <div class="slide-title blue">
                        Unrelated donor transplantation studies
                    </div>


                    <div class="content-container" style="overflow-y:scroll;-webkit-overflow-scrolling: touch">

                        <ul>
                            <li><span>Outcomes associated with unrelated donor transplantation have improved in recent years, but are still not as favourable as that associated with a matched sibling donor</span></li>
                        </ul>

                       <table class="blue">

                            <tr class="odd">
                                <th>Study (Year)</th>
                                <th>Patients, n</th>
                                <th>Conditioning</th>
                                <th>Graft failure, %</th>
                                <th>Median age, years</th>
                                <th>Acute GVHD grade II–IV, %</th>
                                <th>Chronic GVHD, %</th>
                                <th>Survival, %</th>
                            </tr>


                            <tr>
                                <td>Viollier (2008)<sup>1</sup></td>
                                <td>349</td>
                                <td>Various</td>
                                <td>11</td>
                                <td>18.6</td>
                                <td>28</td>
                                <td>22</td>
                                <td>57 (5 years)</td>
                            </tr>


                            <tr class="odd">
                                <td>Kosaka (2008)<sup>2</sup></td>
                                <td>31</td>
                                <td>Cy/ATG/TBI; Flu/Cy/ATG/local field irradiation</td>
                                <td>16</td>
                                <td>8</td>
                                <td>13</td>
                                <td>13</td>
                                <td>93 (3 years)</td>
                            </tr>


                            <tr>
                                <td>Perez-Albuerne (2008)<sup>3</sup></td>
                                <td>195</td>
                                <td>Various</td>
                                <td>15</td>
                                <td>10</td>
                                <td>43</td>
                                <td>35</td>
                                <td>51 (5 years)</td>
                            </tr>


                            <tr class="odd">
                                <td>Bacigalupo (2010)<sup>4</sup></td>
                                <td>100</td>
                                <td>Flu/Cy/ATG; Flu/Cy/ATG-TBI</td>
                                <td>17</td>
                                <td>20</td>
                                <td>18</td>
                                <td>27 (no TBI) 50 (TBI group)</td>
                                <td>75 (5 years)</td>
                            </tr>

                            <tr class="odd">
                                <td>Kang (2010)<sup>5</sup></td>
                                <td>28</td>
                                <td>Flu/Cy/ATG</td>
                                <td>0</td>
                                <td>13.5</td>
                                <td>46.4</td>
                                <td>34.8</td>
                                <td>67.9 (3 years)</td>
                            </tr>


                            <tr>
                                <td>Yagasaki (2010)<sup>6</sup></td>
                                <td>31</td>
                                <td>Various</td>
                                <td>3</td>
                                <td>9</td>
                                <td>37</td>
                                <td>27</td>
                                <td>93.8 (5 years)</td>
                            </tr>


                            <tr class="odd">
                                <td>Lee (2011)<sup>7</sup></td>
                                <td>50</td>
                                <td>Cy/TBI</td>
                                <td>0</td>
                                <td>28</td>
                                <td>46</td>
                                <td>50.3</td>
                                <td>88 (5 years)</td>
                            </tr>
                            
                        </table>

                        <p class="small-print">Outcomes shown are for the entire cohort reported in each study. Studies that include four or more conditioning regimens are reported as “various”. aGVHD, acute GVHD; ATG, antithymocyte globulin; cGVHD, chronic GVHD; Cy, cyclophosphamide; Flu, fludarabine, TBI, total body irradiation.<sup>1</sup></p>

                    </div>

                </div>

                <div class="information4-overlay overlay">

                    <header>Unrelated donor transplantation studies</header>

                    <ul>
                        <li><span>Survival after HLA-matched sibling transplantation can be >80% (for patients aged 20 years or under)<sup>9</sup></span></li>
                        <li><span>Outcomes with unrelated donor (UD) HSCT have improved because of more stringent donor selection<sup>1</sup></span>
                            <ul>
                                <li><span>Facilitated by precision molecular typing, more effective conditioning regimens and a higher quality transfusion and antimicrobial supportive care<sup>1</sup></span></li>
                            </ul>
                        </li>
                        <li><span>However, experience from large cohort studies suggests that the outcome with unrelated HSCT is still not as favourable as that of a matched donor<sup>1</sup></span></li>
                        <li><span>3–5-year survival is highly variable and ranges between 43% and 94%, whereas a study of patients with severe aplastic anaemia (n=1300) who received transplants from a matched sibling donor showed that survival at 5 years was >70% in patients between the ages of 20 and 40<sup>1</sup> </span></li>
                    </ul>


                </div>


                <div class="references4-overlay overlay">

                    <header>References</header>
                        
                    <ol>
                        <li class="navigateHref" data-navtarget="media/documents/module2/ScheinbergP-2012-Blood-v120p1185.pdf"><span>Table adapted from Scheinberg P & Young NS. <i>Blood</i> 2012;120:1185</span></li>
                        <li class="navigateHref" data-navtarget="media/documents/module2/ViollierR-2008-BoneMarrowTransplant-v41p45.pdf"><span>Viollier R <i>et al. Bone Marrow Transplant</i> 2008;41:45</span></li>
                        <li class="navigateHref" data-navtarget="media/documents/module2/KosakaY-2008-Blood-v111p1054.pdf"><span>Kosaka Y <i>et al. Blood</i> 2008;111:1054</span></li>
                        <li class="navigateHref" data-navtarget="media/documents/module2/PerezAlbuerneED-2008-BrJHaematol-v141p216.pdf"><span>Perez-Albuerne ED <i>et al</i>. 2008;141:216</span></li>
                        <li class="navigateHref" data-navtarget="media/documents/module2/BacigalupoA-2010-Haematologica-v95p976.pdf"><span>Bacigalupo A <i>et al. Haematologica</i> 2010;95:976</span></li>
                        <li class="navigateHref" data-navtarget="media/documents/module2/KangHJ-2010-BiolBloodMarrowTransplant-v16p1582.pdf"><span>Kang HJ <i>et al. Biol Blood Marrow Transplant</i> 2010;16:1582</span></li>
                        <li class="navigateHref" data-navtarget="media/documents/module2/YagasakiH-2010-BoneMarrowTransplant-v45p1508.pdf"><span>Yagasaki H <i>et al. Bone Marrow Transplant</i> 2010;45:1508</span></li>
                        <li class="navigateHref" data-navtarget="media/documents/module2/LeeJW-2011-BiolBloodMarrowTransplant-v17p101"><span>Lee JE <i>et al. Biol Blood Marrow Transplant</i> 2011;17:101</span></li>
                        <li class="navigateHref" data-navtarget="media/documents/module2/GuptaV-2010-Haematologica-v95p2119.pdf"><span>Gupta V <i>et al. Haematologica</i> 2010;95:2119</span></li>
                    </ol>

                </div>


          
    </div>
    <!-- End of secondary scene 4 -->
    <!-- Secondary scene 5 -->
    <div class="content secondary-scene">
        <!--<h1>Content</h1>-->
        

                <div class="title-bar blue"></div>

                <div class="wrapper slide-2-6-2-1">

                    <div class="vertical-nav">
                        <ul class="seven">
                            <li></li>
                            <li></li>
                            <li></li>
                            <li></li>
                            <li class="active"></li>
                            <li></li>
                            <li></li>
                        </ul>
                    </div>

                    <div class="popups" style="position:absolute">
                        <div data-effect="fade" data-duration="1000" data-target="references5-overlay" data-width="600" data-height="490" class="references-button show-overlay"></div>
                    </div>

                    <div class="slide-title blue two-line">
                        Survival is lower in patients who receive unrelated donor<br /> transplantation
                    </div>


                    <div class="content-container">
                
                       <table class="wide blue">
                            <tr>
                                <th colspan="3">Survival probability after haematopoietic stem cell transplantation for severe aplastic anaemia, <br />by donor type and age (2000–2010)</th>
                            </tr>

                            <tr>
                                <td>
                                    <img src="media/images/slide_2-6-2-1/picture2.png" alt="">
                                </td>
                            </tr>

                        </table>

                    </div>

                </div>


                <div class="references5-overlay overlay">

                    <header>References</header>
                        
                    <ul>
                        <li class="navigateHref" data-navtarget="media/documents/module2/CentreforInternationalBloodandMarrowTransplantResearch-2012.pdf"><span>Centre for International Blood and Marrow Transplant Research. 2012. http://www.cibmtr.org/ReferenceCenter/SlidesReports/SummarySlides/Pages/index.aspx (accessed October 2013)</span></li>
                    </ul>

                </div>


          
    </div>
    <!-- End of secondary scene 5 -->
    <!-- Secondary scene 6 -->
    <div class="content secondary-scene">
        <!--<h1>Content</h1>-->
        

                <div class="title-bar blue"></div>

                <div class="wrapper slide-2-6-2-1">

                    <div class="vertical-nav">
                        <ul class="seven">
                            <li></li>
                            <li></li>
                            <li></li>
                            <li></li>
                            <li></li>
                            <li class="active"></li>
                            <li></li>
                        </ul>
                    </div>

                    <div class="popups" style="position:absolute">
                        <div data-effect="fade" data-duration="1000" data-target="references6-overlay" data-width="600" data-height="490" class="references-button show-overlay"></div>
                    </div>

                    <div class="slide-title blue">
                        Umbilical cord blood transplantation
                    </div>


                    <div class="content-container">
                
                       <ul>
                           <li><span>Umbilical cord blood (UCB) is attractive as an alternative to unrelated-adult donor grafts, because placental lymphocytes are immunologically naïve<sup>1</sup></span>
                            <ul>
                                <li><span>This would allow for transplantation of UCB units with degrees of donor-recipient disparity that would be undesirable when using bone marrow or peripheral blood grafts</span></li>
                            </ul>
                           </li>
                           <li><span>However, the outcomes of UCB transplantation in patients with severe aplastic anaemia are not encouraging<sup>1</sup></span>
                                <ul>
                                    <li><span>Unpublished data from the Center for International Blood and Marrow Transplant Research (CIBMTR) show an observed graft failure rate of 30% was higher and a 2-year overall survival rate of 35%<sup>1</sup></span>
                                        <ul>
                                            <li><span>Graft failure rate is higher, and 2-year overall survival rate lower than those seen with HLA-matched or mismatched bone marrow grafts<sup>1</sup></span></li>
                                        </ul>
                                    </li>
                                    <li><span>Data from Eurocord (a European organisation promoting research into UCB biology and medical applications of cord cells) also suggest high graft failure rates and 2-year overall survival of approximately 40% associated with unrelated UCB transplantation<sup>2</sup></span></li>
                                </ul>
                           </li>
                       </ul>

                    </div>

                </div>



                <div class="references6-overlay overlay">

                    <header>References</header>
                        
                    <ol>
                        <li class="navigateHref" data-navtarget="media/documents/module2/EapenM-2010-HematolAmSocHematolEducProgram-v2010p43.pdf"><span>Eapen M & Horowitz MM. <i>Hematology Am Soc Hematol Educ Program</i> 2010;2010:43</span></li>
                        <li class="navigateHref" data-navtarget="media/documents/module2/MacMillanML-2010-SeminHematol-v47p37.pdf"><span>MacMillan ML <i>et al. Semin Hematol</i> 2010;47:37</span></li>
                    </ol>

                </div>


          
    </div>
    <!-- End of secondary scene 6 -->
    <!-- Secondary scene 7 -->
    <div class="content secondary-scene">
        <!--<h1>Content</h1>-->
        

                <div class="title-bar blue"></div>

                <div class="wrapper slide-2-6-2-1">

                    <div class="vertical-nav">
                        <ul class="seven">
                            <li></li>
                            <li></li>
                            <li></li>
                            <li></li>
                            <li></li>
                            <li></li>
                            <li class="active"></li>
                        </ul>
                    </div>

                    <div class="popups" style="position:absolute">
                        <div data-effect="fade" data-duration="1000" data-target="references7-overlay" data-width="600" data-height="490" class="references-button show-overlay"></div>
                        <div data-effect="fade" data-duration="1000" data-target="information7-overlay" data-width="600" data-height="490" class="information-button show-overlay"></div> 
                    </div>

                    <div class="slide-title blue">
                        Transplantation protocols
                    </div>


                    <div class="content-container">
                
                       <img style="margin-top:60px" class="center-img" src="media/images/slide_2-6-2-1/picture3.png" alt="">

                    </div>

                </div>

                <div class="information7-overlay overlay">

                    <header>Transplantation protocols</header>

                    <ul>
                        <li><span>There have been different drug combinations over the years, but the popular regimen (also the current standard) includes:</span>
                            <ul>
                                <li><span>Cy + ATG (pre-transplant)<sup>1,2</sup></span>
                                    <ul>
                                        <li><span>However, a randomised controlled trial found that this combination was not superior to Cy alone<sup>4</sup></span></li>
                                    </ul>
                                </li>
                                <li><span>CsA and methotrexate for GVHD prophylaxis<sup>3</sup></span></li>
                            </ul>
                        </li>
                        <li><span>Adding fludarabine (Flu) to Cy/ATG has been shown to overcome the risk of rejection in heavily transfused or older patients undergoing matched sibling HSCT, and may be an option in this patient group<sup>2,5</sup></span></li>
                        <li><span>Alemtuzumab has been investigated as a replacement for ATG in transplant protocols and may mitigate the impact of GVHD<sup>6</sup></span>
                            <ul>
                                <li><span>2-year survival of >80% for both matched sibling and unrelated HSCT<sup>6</sup></span></li>
                                <li><span>Acute GVHD was observed in 13.5% of patients; 4% developed GVHD<sup>6</sup></span></li>
                            </ul>
                        </li>
                        <li><span>When considering UD HSCT, the following should be noted:<sup>2</sup></span>
                            <ul>
                                <li><span>It is currently unclear what the optimal conditioning regimen is in the UD setting</span></li>
                                <li><span>Low-dose total body irradiation may be included in pre-transplant conditioning to ensure engraftment (transplant acceptance) and to potentially reduce long-term risks associated with radiation exposure at a young age</span></li>
                            </ul>
                        </li>
                    </ul>


                </div>


                <div class="references7-overlay overlay">

                    <header>References</header>
                        
                    <ol>
                        <li class="navigateHref" data-navtarget="media/documents/module2/DeZernA-2011-ExpertRevHematol-v4p221.pdf"><span>DeZern AE & Brodsky RA. <i>Exp Rev Hematol</i> 2011;4:221</span></li>
                        <li class="navigateHref" data-navtarget="media/documents/module2/ScheinbergP-2012-HematologyAmSocHematolEducPogram-v2012p292.pdf"><span>Scheinberg P. <i>Hematology Am Soc Hematol Educ Program</i> 2012;292</span></li>
                        <li class="navigateHref" data-navtarget="media/documents/module2/YoungNS-2010-BiolBloodBoneMarrowTransplant-v16pS119.pdf"><span>Young NS <i>et al. Biol Blood Bone Marrow Transplant</i> 2010;16:S119</span></li>
                        <li class="navigateHref" data-navtarget="media/documents/module2/ChamplinRE-2007-Blood-v109p4562.pdf"><span>Champlin RE <i>et al. Blood</i> 2007;109:4582</span></li>
                        <li class="navigateHref" data-navtarget="media/documents/module2/MauryS-2009-Haematologica-v94p1312.pdf"><span>Maury S <i>et al. Haematologica</i> 2009;94:1312</span></li>
                        <li class="navigateHref" data-navtarget="media/documents/module2/MarshJ-2011-Blood-v118p2351.pdf"><span>Marsh JC <i>et al. Blood</i> 2011;118:2351</span></li>
                    </ol>

                </div>


          
    </div>
    <!-- End of secondary scene 7 -->
    </div>
 </div>